Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced it signed an exclusive research and development agreement with Constance Therapeutics for the development and potential commercialization of medical cannabis extract products in Canada.
As quoted in the press release:
In addition to this agreement, the Company further strengthens its R&D program by means of a National Sciences and Engineering Research Council of Canada (NSERC) grant in its collaborative project with Dr Stan Kubow at McGill university.
Constance Therapeutics has developed whole plant cannabis extracts that have shown significant clinical promise in the treatment of various forms of cancer and improved patient survival as well. In collaboration, Tetra and Constance Therapeutics now aim to define the therapeutic mechanism and demonstrate efficacy of these cannabis extracts in the treatment of human cancers. In accordance with Tetra’s provisional patent announced on May 17th, 2017, the collaboration will focus on treating various forms of cancer driven by inappropriate Hedgehog signaling, including multiple forms of brain, blood, skin and bone cancers.